A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion Study to Evaluate the Safety and Clinical Activity of PBCAR269A in Study Participants with Relapsed/Refractory Multiple Myeloma
Study of PBCAR269A in Participants With Relapsed/Refractory Multiple Myeloma
Sponsor: Precision BioSciences, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS9451
U.S. Govt. ID: NCT04171843
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this research study is to obtain information on the safety and effectiveness of PBCAR269A to treat certain types of cancers. PBCAR269A is a new investigational treatment for certain types of cancer of the blood, such as multiple myeloma. It is made from a type of blood cells known as T cells. The T cells in PBCAR269A came from people who have donated their blood. The donated T cells have been genetically changed, so that they may be able to kill some types of cancer cells.
This study is closed
Investigator
Ran Reshef, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with multiple myeloma that has come back or has not responded to treatment? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE